Genome Editing of Human Primary Keratinocytes by CRISPR/Cas9 Reveals an Essential Role of the NLRP1 Inflammasome in UVB Sensing

被引:83
|
作者
Fenini, Gabriele [1 ]
Grossi, Serena [1 ]
Contassot, Emmanuel [1 ,2 ]
Biedermann, Thomas [3 ]
Reichmann, Ernst [3 ]
French, Lars E. [1 ,2 ]
Beer, Hans-Dietmar [1 ,2 ]
机构
[1] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland
[2] Univ Zurich, Fac Med, Zurich, Switzerland
[3] Univ Childrens Hosp Zurich, Tissue Biol Res Unit, Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
EPIDERMAL-KERATINOCYTES; GENETIC-VARIATIONS; LENTIVIRAL VECTOR; GASDERMIN D; ACTIVATION; SKIN; CULTIVATION; VITILIGO; INTERLEUKIN-1-BETA; SUSCEPTIBILITY;
D O I
10.1016/j.jid.2018.07.016
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
By forming a protective barrier, epidermal keratinocytes represent the first line of defense against environmental insults. UVB radiation of the sun is a major challenge for the skin and can induce inflammation, aging, and eventually skin cancer. UVB induces an immune response in human keratinocytes resulting in activation and secretion of the proinflammatory cytokines proIL-1 beta and -18. This is mediated by an assembly of protein complexes, termed inflammasomes. However, the mechanisms underlying sensing of UVB by keratinocytes, and particularly the types of inflammasomes required for cytokine secretion, are a matter of debate. To address these questions, we established a protocol that allows the generation of CRISPR/Cas9-targeted human primary keratinocytes. Our experiments showed an essential role of the NLRP1 rather than the NLRP3 inflammasome in UVB sensing and subsequent IL-1 beta and -18 secretion by keratinocytes. Moreover, NLRP1 but not NLRP3 was required for inflammasome activation in response to nigericin, a potassium ionophore and well-established NLRP3 activator in immune cells. Because the CRISPR/Cas9-targeted cells retained their full differentiation capacity, genome editing of human primary keratinocytes might be useful for numerous research and medical applications.
引用
收藏
页码:2644 / 2652
页数:9
相关论文
共 50 条
  • [21] RETRACTION: "CRISPR/Cas9: A Revolutionary Genome Editing Tool for Human Cancers Treatment"
    Akram, F.
    Ul, Haq, I
    Sahreen, S.
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [22] OPTIMISING TARGETED GENOME EDITING OF THE HUMAN β-GLOBIN LOCUS USING CRISPR/CAS9
    Glaser, Astrid
    McColl, Brad
    Abu-Bonsrah, Dad
    Elefanty, Andrew
    Vadolas, Jim
    JOURNAL OF GENE MEDICINE, 2015, 17 (8-9): : 207 - 208
  • [23] Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy
    Gori, Jennifer L.
    Hsu, Patrick D.
    Maeder, Morgan L.
    Shen, Shen
    Welstead, G. Grant
    Bumcrot, David
    HUMAN GENE THERAPY, 2015, 26 (07) : 443 - 451
  • [24] CRISPR/Cas9 Mice Genome Editing to Study New Human Deafness Genes
    Abu-Rayyan, Amal
    Bordeynik-Cohen, Mor
    Taiber, Shahar
    Koffler-Brill, Tal
    Rosen, Einat
    Carlson, Ryan
    Haffner, Rebecca
    Kanaan, Moien
    King, Mary-Claire
    Avraham, Karen B.
    TRANSGENIC RESEARCH, 2020, 29 (SUPPL 1) : 11 - 11
  • [25] CRISPR/Cas9 viral like particles for targeted genome editing in human cells
    Petris, G.
    Montagna, C.
    Casini, A.
    Maule, G.
    Zanella, I.
    Zacchigna, S.
    Zentilin, L.
    Giacca, M.
    Cereseto, A.
    HUMAN GENE THERAPY, 2016, 27 (11) : A131 - A131
  • [26] RETRACTED: CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment
    Akram, Fatima
    Ul Haq, Ikram
    Sahreen, Sania
    Nasir, Narmeen
    Naseem, Waqas
    Imitaz, Memoona
    Aqeel, Amna
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [27] Application of the genome editing tool CRISPR/Cas9 in non-human primates
    Luo, Xin
    Li, Min
    Su, Bing
    ZOOLOGICAL RESEARCH, 2016, 37 (04) : 214 - 219
  • [28] Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells
    Hindriksen, Sanne
    Bramer, Arne J.
    My Anh Truong
    Vromans, Martijn J. M.
    Post, Jasmin B.
    Verlaan-Klink, Ingrid
    Snippert, Hugo J.
    Lens, Susanne M. A.
    Hadders, Michael A.
    PLOS ONE, 2017, 12 (06):
  • [29] Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9
    Wang, Yanlin
    Hao, Lei
    Wang, Hongcai
    Santostefano, Katherine
    Thapa, Arjun
    Cleary, John
    Li, Hui
    Guo, Xiuming
    Terada, Naohiro
    Ashizawa, Tetsuo
    Xia, Guangbin
    MOLECULAR THERAPY, 2018, 26 (11) : 2617 - 2630
  • [30] THERAPEUTIC GENOME EDITING FOR MYOTONIC DYSTROPHY TYPE 1 USING CRISPR/CAS9
    Xia, G.
    Wang, Y.
    Hao, L.
    Wang, H.
    Santostefano, K.
    Thapa, A.
    Cleary, J.
    Li, H.
    Guo, X.
    Terada, N.
    Ashizawa, T.
    MUSCLE & NERVE, 2018, 58 : S2 - S2